Vertex announces u.s. fda approval for trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 2 through 5 with certain mutations

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced the u.s. food and drug administration (fda) approved the expanded use of trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (cf) ages 2 through 5 years who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene or a mutation in the cftr gene that is responsive to trikafta® based on in vitro data. trikafta®.
VRTX Ratings Summary
VRTX Quant Ranking